Anti-vascular endothelial growth factor therapy in the era of personalized medicine (Q38086799)

28 August 2017

title

Anti-vascular endothelial growth factor therapy in the era of personalized medicine (English)

1 reference

Apostolia Maria Tsimberidou

28 August 2017

0 references

personalized medicine

1 reference

based on heuristic

inferred from title

author

series ordinal

2

object named as

Apostolia M Tsimberidou

1 reference

28 August 2017

Luis R Féliz

1

1 reference

28 August 2017

publication date

6 March 2013

1 reference

Cancer Chemotherapy and Pharmacology

28 August 2017

published in

1 reference

28 August 2017

volume

72

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

1-12

1 reference

What Is the Evidence That Tumors Are Angiogenesis Dependent?

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Angiogenic inhibitors: a new therapeutic strategy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Vasculogenic mimicry and pseudo-comedo formation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Angiogenesis as a strategic target for ovarian cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Vascular endothelial growth factor expression in early stage ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Targeting angiogenesis in esophagogastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

The von Hippel-Lindau tumor suppressor gene and kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Tumor regression by targeted gene delivery to the neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Pazopanib: Clinical development of a potent anti-angiogenic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Notch signaling in developmental and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2124-Y

10.1007/S00280-013-2124-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1017500360

0 references

1 reference